Clinical Trial Update: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension [Phase 3]

View source ↗

Summary

A Phase 3 open-label extension of tadekinig alfa for XIAP deficiency and NLRC4-associated macrophage activation syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nlrc4-associated Macrophage Activation Syndrome
• Xiap Deficiency

Drugs mentioned

• Tadekinig Alfa (tadekinig alfa)

Snippet

Sponsor: AB2 Bio Ltd. | Conditions: XIAP Deficiency, NLRC4-MAS | Phase 3 | Status: COMPLETED